Recursion Pharmaceuticals
RXRX
4.27
-0.36
-7.78%
Recursion Pharmaceuticals
US · RXRX
#2649 by market cap
Listed 2021
4.27
-0.36
-7.78%
Live - 5344 symbols - heartbeat 563s ago
· 2026-10-08 06:48
Pre-market
4.18
-2.06%
After-hours
4.27
0.00%
Overnight
4.26
-0.23%
- Market cap
- 2.29B
- P/E (TTM)i
- -4.27
- P/Bi
- 2.50
- EPSi
- -1.44
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on RXRX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 5 analysts
Buy
Avg price target
6.65 +55.7%
Price target rangecurrent 4.27
Low5.30
Avg6.65
High8.00
Buy 40%
Hold 60%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-21 | BofA Securities | -- | HOLD | -- |
| 2026-09-15 | J.P. Morgan | -- | BUY | -- |
| 2026-08-17 | Morgan Stanley | -- | HOLD | 5.30 |
| 2026-08-12 | BofA Securities | -- | HOLD | 6.00 |
| 2026-08-07 | BofA Securities | -- | HOLD | 6.00 |
| 2026-08-05 | TD Cowen | -- | HOLD | -- |
| 2026-08-05 | Needham | -- | BUY | 8.00 |
| 2026-05-14 | Morgan Stanley | -- | HOLD | 5.50 |
| 2026-05-13 | BofA Securities | -- | HOLD | 6.00 |
| 2026-05-07 | BofA Securities | -- | HOLD | 6.00 |
| 2026-05-07 | Needham | -- | BUY | 8.00 |
| 2026-05-06 | TD Cowen | -- | HOLD | -- |
| 2026-04-30 | J.P. Morgan | -- | BUY | 10.00 |
| 2026-04-14 | Needham | -- | BUY | 8.00 |
| 2026-02-25 | TD Cowen | -- | HOLD | -- |
| 2026-02-25 | BofA Securities | -- | HOLD | 6.00 |
| 2026-02-25 | Needham | -- | BUY | 8.00 |
| 2026-01-14 | BofA Securities | -- | HOLD | 7.00 |
| 2026-01-12 | BofA Securities | -- | HOLD | 7.00 |
| 2026-01-06 | BofA Securities | -- | HOLD | 7.00 |
| 2025-12-17 | J.P. Morgan | -- | BUY | 11.00 |
| 2025-12-08 | BofA Securities | -- | HOLD | 7.00 |
| 2025-12-08 | Morgan Stanley | -- | HOLD | 5.00 |
| 2025-12-08 | Needham | -- | BUY | 8.00 |
| 2025-11-05 | TD Cowen | -- | HOLD | -- |
Quant vs Street three independent views, side by side
StockVane factor grade
D+
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | -- | ±8.09% | -4.23% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±8.09% | +1.78% (in line) |
| 2025/Q4 | 2026-02-25 | -- | ±7.60% | +6.80% (in line) |
| 2025/Q3 | 2025-11-05 | -- | ±10.60% | -0.80% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±13.93% | -4.66% (in line) |
| 2025/Q1 | 2025-05-05 | -- | ±16.77% | -16.58% (in line) |
| 2024/Q4 | 2025-02-28 | -- | ±15.97% | -2.09% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±14.48% | -0.57% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±22.81% | +4.24% (in line) |
| 2024/Q1 | 2024-05-09 | After close | ±13.75% | -0.46% (in line) |
| 2023/Q4 | 2024-02-27 | After close | -- | -16.62% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:48:47 · For reference only, not investment advice and not tailored to your situation.